Navigation Links
Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose

Trial Convincingly Proves Functionality in Humans of CTI's Programmable, Pulsatile, Passive Transdermal Drug Delivery Device - ChronoDose

BASEL, Switzerland and TRENTON, N.J., May 03, 2007 /PRNewswire/ -- Chrono Therapeutics Inc. (CTI) announced today the successful completion of its first phase human clinical trial of its programmable, pulsatile, passive transdermal drug/device combination product: ChronoDose(TM). CTI intends to publish this clinical data in leading scientific and medical journals by year end.

CLINICAL STUDY DESIGN

The trial was conducted between February and April 2007 at the University Hospital Basel, Switzerland, Division of Clinical Pharmacology and Toxicology. Georgios Imanidis, PhD, of the University of Basel was the Principal Investigator on behalf of CTI.

This study was an open, randomized, three period, single-center, dose- escalation study. Thirty-six independent human transdermal tests were conducted on male volunteers using wristwatch-like ChronoDose(TM) devices. The trial successfully proved the efficacy of the device on human subjects using its model drug compound. The dose escalation trial showed statistically significant modulation and control of the dosing profiles. Using low, medium and high concentrations, for 16 hours, the model drug permeated each subject's skin on multiple occasions, resulting in clear and distinct peaks and troughs of therapeutically effective and well-targeted blood plasma concentration levels. A non-compartmental and compartmental model based analysis of pharmacokinetics will be utilized. Local and systemic tolerability of the model drug after its transdermal administration was better than planned.

Dr. Georgios Imanidis commented, "CTI has for the first time in transdermal drug delivery history successfully completed a significant human trial with a passive, automated and programmable multiple dosing transdermal device syste
'"/>




Page: 1 2 3

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
3. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
4. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
5. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
9. Sosei Announces Successful Completion of AD 923 Pharmacokinetic Study in the USA
10. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
11. SkyePharma and Sciele Pharma Announce Successful Completion of New Sular Formulation Clinical Trial Programme
Post Your Comments:
(Date:8/3/2015)... YORK , August 3, 2015 ... published by Persistence Market Research "Global Market Study ... to Witness Highest Growth by 2022", the ... US$15 Bn by the end of 2015 and is ... from 2015 to 2022, to account for US$23.7 ...
(Date:8/3/2015)... SPRINGS, Florida , August 3, 2015 ... development agreements between biotech companies, military surgical ... solutions & therapies with regards to severe ... positive clinical enhancements for regenerative medicine and ... recent developments, partnerships and advancements in focus ...
(Date:8/3/2015)... , Aug. 3, 2015 VWR (NASDAQ: ... services and solutions, announces the redesign of its global website, ... When visiting the new site, guests will enjoy ... colors and vivid images.  Each country site now includes: ... to Z product menu; and , the ability to ...
Breaking Medicine Technology:Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6VWR's New Website Redesign Provides Improved Functionality for Customers 2
... results, SAN DIEGO, April 9, 2008 ... Meeting suggest that an all-natural dietary,supplement made from ... lower,their blood glucose numbers after a meal and ... PhD, KGK Synergize Inc.,s Scientific Director,said, "Our scientifically ...
... Calif., April 9, 2008 ,Sunesis Pharmaceuticals, Inc. (Nasdaq: ... present data on each of its clinical-stage anticancer,compounds ... Association for,Cancer Research (AACR) being held April 12-16 ... of product candidates in oncology focused on novel,pathways ...
Cached Medicine Technology:People With Diabetes May Have All-Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels 2People With Diabetes May Have All-Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels 3Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research 2Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research 3
(Date:8/3/2015)... ... 2015 , ... Bayer has agreed to pay $56.9 million to set up ... alleged to have suffered an arterial blood clot including stroke and heart attack. The ... Ocella, has been ongoing for well-over five years. In 2009, lawsuits filed against Bayer ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s ... offer pharmacogenetic lab testing and precision medicine solutions that can help pharmacists and ... Annually, more than 8.6 million adverse drug events are reported in the U.S. ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social ... , AUGUST 3, 2015 – Since winning a South by Southwest® (SXSW®) Interactive ... – an organization whose mission is to develop technology for the sake of ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... it’s new program “Designing Secure Healthcare Systems” This three-day, highly interactive and ... from healthcare organizations with access to the tactics, techniques and practices required to ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... is predicted to decline by 39 percent, according to market research compiled for ... includes data from the U.S. Department of Labor, Bureau of Labor Statistics. As ...
Breaking Medicine News(10 mins):Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3
... A novel research finding from the investigators of Ohio ... of combination of metals like copper with organic chemicals ... range of diseases that are caused by virus.// ... of HIV and Hepatitis C virus RNA in the ...
... of middle-aged women and is characterized by recurring discomfort ... Symptoms vary and can include a combination of mild ... and pelvic area; and an urgent and/or frequent need ... become scarred or irritated, and pinpoint bleeding may appear ...
... HIV infection among its cadres, the Border Security Force ... outpost along West Bengal's international boundary. // ... launched in collaboration with the state AIDS control society ... troopers. ,"We are setting up these condom counters ...
... household activities like cleaning the house and the backyards, ... of prehypertension in people. // ,The study ... daily lifestyle physical activity had the effect of dropping ... hypertensive to prehypertensive and from prehypertensive to normal -- ...
... discriminate between self and non-self. If not for the ... would have lost its power to fight against diseases ... system produces certain substances called antibodies, which identify the ... "bad" so that other divisions of the immune system ...
... strong and science weak, men mistook magic for medicine; now, ... for magic. ~Thomas Szasz, The Second Sin, 1973 ... regarded as a forbidden organ too delicate to tamper with. ... World War II. Military doctors, facing injury and suffering on ...
Cached Medicine News:Health News:Metal In Medicines Can Fight Diseases Effectively 2Health News:Marijuana-Derived Drug Promises Hope In Treating Bladder Infection 2Health News:Free Condom Counters For Border Security Force Cadres 2Health News:Fighting against disease as easy as eating eggs 2Health News:Statins Taken For Reducing Cholesterol Found To Reduce Death Rate Associated With Heart Attack As Well 2
... System includes: Mx3005P instrument and custom ... five (5) filters. The standard filter ... HEX/JOE/VIC (535nm-555nm), ROX/Texas Red (585nm-610nm), Cy5 ... includes notebook computer, Mx3005P analysis software, ...
... temperature cyclers, the gradient block can be set ... to 14 or 22 across the 40- or ... up to 2C between adjacent wells in each ... 12 different annealing temperatures in a single experiment. ...
... The system includes: Mx3005P instrument and ... of five (5) filters. The standard ... (492nm-516nm), HEX/JOE/VIC (535nm-555nm), ROX/Texas Red (585nm-610nm), ... included: desktop computer, Mx3005P analysis software, ...
... includes: Mx3005P instrument and custom filter ... (5) filters. The standard filter set ... (535nm-555nm), ROX/Texas Red (585nm-610nm), Cy5 (635nm-665nm) ... computer, Mx3005P analysis software, Beacon Designer ...
Medicine Products: